
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Compliance from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/compliance/topic/2090/</link>
        <description>Articles tagged with Compliance from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>GSK&apos;s Connelly: We&apos;ve changed our ways (and please don&apos;t imprison execs)</title>
          <description>GlaxoSmithKline&apos;s Dierdre Connelly peeled back the curtain on the company&apos;s sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.</description>
          <link>http://www.mmm-online.com/gsks-connelly-weve-changed-our-ways-and-please-dont-imprison-execs/article/267037/</link>
          <pubDate>Mon, 05 Nov 2012 20:56:09 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline&apos;s Dierdre Connelly peeled back the curtain on the company&apos;s sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Pharma execs: MLR teams are friendlier on digital</title>
          <description>Pharma&apos;s med/legal/regulatory (MLR) teams, managers of risk and so often the scapegoats for creating roadblocks to digital innovation, were discussed in a much friendlier light by digital marketers at last week&apos;s ExL Digital Pharma East conference in Philadelphia.</description>
          <link>http://www.mmm-online.com/pharma-execs-mlr-teams-are-friendlier-on-digital/article/264723/</link>
          <pubDate>Mon, 22 Oct 2012 19:31:23 GMT</pubDate>
          <itunes:summary>Pharma&apos;s med/legal/regulatory (MLR) teams, managers of risk and so often the scapegoats for creating roadblocks to digital innovation, were discussed in a much friendlier light by digital marketers at last week&apos;s ExL Digital Pharma East conference in Philadelphia.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>GSK seeks to span digital divide with social/digital dragnet</title>
          <description>GlaxoSmithKline is souping up its social media monitoring with a digital strategy it says will create processes that are standard enough to streamline communications, but flexible enough to meet local requirements.</description>
          <link>http://www.mmm-online.com/gsk-seeks-to-span-digital-divide-with-socialdigital-dragnet/article/232700/</link>
          <pubDate>Mon, 19 Mar 2012 19:21:07 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline is souping up its social media monitoring with a digital strategy it says will create processes that are standard enough to streamline communications, but flexible enough to meet local requirements.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>GSK hopes $3-bil. off-label settlement will end legal woes</title>
          <description>GlaxoSmithKline&apos;s deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.</description>
          <link>http://www.mmm-online.com/gsk-hopes-3-bil-off-label-settlement-will-end-legal-woes/article/216216/</link>
          <pubDate>Mon, 07 Nov 2011 22:07:21 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline&apos;s deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Omnicom, CAHG sign up for regulatory compliance training</title>
          <description>Agency CAHG became the first healthcare marketing shop to undergo training and certification in regulatory compliance through the Center for Communication Compliance, and its parent company, Omnicom, said all of its healthcare agencies will follow suit.</description>
          <link>http://www.mmm-online.com/omnicom-cahg-sign-up-for-regulatory-compliance-training/article/216076/</link>
          <pubDate>Fri, 04 Nov 2011 21:06:52 GMT</pubDate>
          <itunes:summary>Agency CAHG became the first healthcare marketing shop to undergo training and certification in regulatory compliance through the Center for Communication Compliance, and its parent company, Omnicom, said all of its healthcare agencies will follow suit.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Merck web widget points to future adherence fix</title>
          <description>Asking consumers to gauge their risk for non-adherence, Merck is deploying a one-minute survey dubbed the Adherence Estimator that may be the way forward for keeping patients on-treatment.</description>
          <link>http://www.mmm-online.com/merck-web-widget-points-to-future-adherence-fix/article/213574/</link>
          <pubDate>Tue, 04 Oct 2011 18:29:23 GMT</pubDate>
          <itunes:summary>Asking consumers to gauge their risk for non-adherence, Merck is deploying a one-minute survey dubbed the Adherence Estimator that may be the way forward for keeping patients on-treatment.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Majority of pharma journal ads not FDA-compliant: study</title>
          <description>Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the &quot;Bad Ad&quot; program.</description>
          <link>http://www.mmm-online.com/majority-of-pharma-journal-ads-not-fda-compliant-study/article/209829/</link>
          <pubDate>Wed, 17 Aug 2011 21:26:55 GMT</pubDate>
          <itunes:summary>Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the &quot;Bad Ad&quot; program.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Feds subpoena Merck on marketing of hepatitis, cancer drugs</title>
          <description>Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.</description>
          <link>http://www.mmm-online.com/feds-subpoena-merck-on-marketing-of-hepatitis-cancer-drugs/article/209287/</link>
          <pubDate>Mon, 08 Aug 2011 21:11:29 GMT</pubDate>
          <itunes:summary>Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Pain drug monitoring firm enticed docs to use test, qui-tam suit charges</title>
          <description>A national lab promised doctors they could enrich themselves by as much as $2 million a year through a scheme that involved billing payers multiple times for the same urinary drug test, a whistleblower suit alleges.</description>
          <link>http://www.mmm-online.com/pain-drug-monitoring-firm-enticed-docs-to-use-test-qui-tam-suit-charges/article/206884/</link>
          <pubDate>Wed, 06 Jul 2011 16:51:36 GMT</pubDate>
          <itunes:summary>A national lab promised doctors they could enrich themselves by as much as $2 million a year through a scheme that involved billing payers multiple times for the same urinary drug test, a whistleblower suit alleges.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Mobile pill cap takes social approach to raising compliance</title>
          <description>A company that markets a pill cap with a built-in cellular connection puts a social twist on getting patients to take their meds.</description>
          <link>http://www.mmm-online.com/mobile-pill-cap-takes-social-approach-to-raising-compliance/article/174102/</link>
          <pubDate>Wed, 07 Jul 2010 19:57:53 GMT</pubDate>
          <itunes:summary>A company that markets a pill cap with a built-in cellular connection puts a social twist on getting patients to take their meds.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  